机构：[1]Medical Oncology, Shanghai Chest Hospital, Shanghai, China[2]The 3rd Departmentof Thoracic Oncology, Affiliated Tumor Hospital of Harbin Medical University, Harbin,China[3]Medical Oncology, Zhejiang Cancer Hospital, Hangzhou, China浙江省肿瘤医院[4]Oncology,Hubei Cancer Hospital, Wuhan, China[5]The Affiliated Cancer Hospital of ZhengzhouUniversity, Henan Cancer Hospital, Zhengzhou, China河南省肿瘤医院[6]Oncology, The First AffiliatedHospital of Zhengzhou University, Zhengzhou, China[7]Medical Oncology, Fujian CancerHospital, Fuzhou, China[8]Medical Oncology, The First Hospital of China MedicalUniversity, Shenyang, China[9]Medical Oncology, Cancer Center of Guangzhou MedicalUniversity, Guangzhou, China[10]Cancer Center, The First Hospital of Jilin University,Changchun, China[11]Third Military Medical University, Daping Hospital, Chongqing,China[12]Oncology, Nanfang Hospital of Southern Medical University, Guangzhou,China[13]Medical Oncology, Peking Union Medical College Hospital, Beijing, China[14]Medical Oncology, The First Affiliated Hospital of Zhejiang University, Hangzhou,China浙江大学医学院附属第一医院[15]Department of Internal Medicine-Oncology, Shandong Cancer Hospital, Jinan,China[16]Oncology, Jinan Central Hospital, Jinan, China[17]Clinical Development, Bei-Gene (Beijing) Co., Ltd., Beijing, China[18]Biostatistics, BeiGene (Beijing) Co., Ltd.,Beijing, China[19]Clinical Biomarker, BeiGene (Beijing) Co., Ltd., Beijing, China[20]Department of Internal Medicine, Cancer Hospital Chinese Academy of MedicalSciences, Beijing, China
第一作者机构：[1]Medical Oncology, Shanghai Chest Hospital, Shanghai, China
推荐引用方式(GB/T 7714)：
S. Lu,Y. Yu,X. Yu,et al.Tislelizumab plus chemotherapy vs chemotherapy alone as first-line treatment for locally advanced/metastatic nonsquamous NSCLC[J].ANNALS OF ONCOLOGY.2020,31:S816-S817.doi:10.1016/j.annonc.2020.08.1577.
APA：
S. Lu,Y. Yu,X. Yu,Y. Hu,Z. Ma...&J. Wang.(2020).Tislelizumab plus chemotherapy vs chemotherapy alone as first-line treatment for locally advanced/metastatic nonsquamous NSCLC.ANNALS OF ONCOLOGY,31,
MLA：
S. Lu,et al."Tislelizumab plus chemotherapy vs chemotherapy alone as first-line treatment for locally advanced/metastatic nonsquamous NSCLC".ANNALS OF ONCOLOGY 31.(2020):S816-S817
医学